TW202530257A - 包含靶向il-13及tslp之免疫球蛋白單可變域的多肽 - Google Patents
包含靶向il-13及tslp之免疫球蛋白單可變域的多肽Info
- Publication number
- TW202530257A TW202530257A TW113137609A TW113137609A TW202530257A TW 202530257 A TW202530257 A TW 202530257A TW 113137609 A TW113137609 A TW 113137609A TW 113137609 A TW113137609 A TW 113137609A TW 202530257 A TW202530257 A TW 202530257A
- Authority
- TW
- Taiwan
- Prior art keywords
- amino acid
- seq
- acid sequence
- isvd
- cdr1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945391P | 2019-12-09 | 2019-12-09 | |
| US62/945,391 | 2019-12-09 | ||
| EP20305064 | 2020-01-27 | ||
| EP20305064.6 | 2020-01-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202530257A true TW202530257A (zh) | 2025-08-01 |
Family
ID=73793214
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW113137609A TW202530257A (zh) | 2019-12-09 | 2020-12-09 | 包含靶向il-13及tslp之免疫球蛋白單可變域的多肽 |
| TW109143498A TWI861302B (zh) | 2019-12-09 | 2020-12-09 | 包含靶向il-13及tslp之免疫球蛋白單可變域的多肽 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109143498A TWI861302B (zh) | 2019-12-09 | 2020-12-09 | 包含靶向il-13及tslp之免疫球蛋白單可變域的多肽 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US20210188965A1 (https=) |
| EP (1) | EP4072674A1 (https=) |
| JP (2) | JP7641968B2 (https=) |
| KR (1) | KR20220123237A (https=) |
| CN (1) | CN114980974A (https=) |
| AU (1) | AU2020400938A1 (https=) |
| BR (1) | BR112022010223A2 (https=) |
| CA (1) | CA3163910A1 (https=) |
| CO (1) | CO2022008813A2 (https=) |
| IL (1) | IL293548A (https=) |
| MX (1) | MX2022007035A (https=) |
| MY (1) | MY208649A (https=) |
| TW (2) | TW202530257A (https=) |
| WO (1) | WO2021116182A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6871948B2 (ja) | 2016-04-27 | 2021-05-19 | アッヴィ・インコーポレイテッド | 抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法 |
| MX2022007035A (es) | 2019-12-09 | 2022-06-23 | Ablynx Nv | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp. |
| AU2021350156A1 (en) | 2020-09-25 | 2023-06-08 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l |
| IL308360A (en) * | 2021-05-30 | 2024-01-01 | Biolojic Design Ltd | Engineered dual binding antibodies and uses thereof |
| EP4540284A2 (en) | 2022-06-17 | 2025-04-23 | Apogee Therapeutics, Inc. | Antibodies that bind interleukin 13 and methods of use |
| US20240117038A1 (en) * | 2022-07-18 | 2024-04-11 | Ablynx N.V. | Cx3cr1-binding compounds, methods and uses thereof |
| CN118005784A (zh) * | 2022-11-08 | 2024-05-10 | 上海洛启生物医药技术有限公司 | 抗il-13长效纳米抗体序列及其应用 |
| AR131494A1 (es) | 2022-12-23 | 2025-03-26 | Ablynx Nv | Vehículos de conjugación a base de proteína |
| TW202448926A (zh) | 2023-02-17 | 2024-12-16 | 比利時商艾伯霖克斯公司 | 結合新生兒fc受體之多肽 |
| EP4435005A1 (en) | 2023-03-24 | 2024-09-25 | Sanofi | Asthma treatment by blocking il-13 and tslp |
| AU2024247861A1 (en) | 2023-03-24 | 2025-11-06 | Sanofi | Asthma treatment by blocking il-13 and tslp |
| CN121816362A (zh) * | 2023-06-22 | 2026-04-07 | 派拉冈医疗公司 | 结合白细胞介素13和tslp或tslpr的抗体及其使用方法 |
| AU2024334289A1 (en) | 2023-08-25 | 2026-04-09 | Proteologix Us Inc. | Anti-il-13 multispecific antibody constructs and uses thereof |
| AR134102A1 (es) * | 2023-10-12 | 2025-12-03 | Innovent Biologics Suzhou Co Ltd | ANTICUERPOS ANTI-IL-4Ra Y USOS DE LOS MISMOS |
| WO2025209486A1 (en) * | 2024-04-02 | 2025-10-09 | Keymed Biosciences (Chengdu) Co., Ltd. | Antibodies targeting il-13 and tslp and uses thereof |
| WO2026041740A1 (en) | 2024-08-21 | 2026-02-26 | Sanofi | Treatment of high-risk asthma by blocking il-13 and tslp |
| WO2026055143A2 (en) * | 2024-09-03 | 2026-03-12 | Attovia Therapeutics, Inc. | Il13-binding polypeptides and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| DK1027439T3 (da) | 1997-10-27 | 2010-05-10 | Bac Ip Bv | Multivalente antigenbindende proteiner |
| WO2004041863A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses therefor |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| US8188223B2 (en) | 2005-05-18 | 2012-05-29 | Ablynx N.V. | Serum albumin binding proteins |
| AU2007237501A1 (en) | 2006-04-14 | 2007-10-25 | Ablynx N.V. | DP-78-like nanobodies |
| WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| AU2007293614A1 (en) * | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| JP5059119B2 (ja) * | 2006-12-14 | 2012-10-24 | シェーリング コーポレイション | 操作された抗ｔｓｌｐ抗体 |
| KR20110092328A (ko) * | 2008-11-26 | 2011-08-17 | 글락소 그룹 리미티드 | Ｉｌ-13에 결합하는 리간드 |
| SG10201805064SA (en) | 2011-06-23 | 2018-07-30 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP2723771B1 (en) | 2011-06-23 | 2019-09-11 | Ablynx NV | Serum albumin binding proteins |
| EP4707303A2 (en) | 2014-05-16 | 2026-03-11 | Ablynx NV | Improved immunoglobulin variable domains |
| KR20170123315A (ko) * | 2015-03-11 | 2017-11-07 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Tslp 결합 단백질 |
| LT3374392T (lt) | 2015-11-13 | 2022-01-25 | Ablynx Nv | Patobulinti serumo albuminą surišantys imunoglobulino kintami domenai |
| CA3003777A1 (en) * | 2015-11-18 | 2017-05-26 | Merck Sharp & Dohme Corp. | Pd1/ctla4 binders |
| AU2016357460B2 (en) | 2015-11-18 | 2023-07-27 | Ablynx Nv | Improved serum albumin binders |
| KR20180080337A (ko) * | 2015-11-27 | 2018-07-11 | 아블린쓰 엔.브이. | Ｃｄ40ｌ을 억제하는 폴리펩티드 |
| EP3426278B1 (en) * | 2016-03-07 | 2024-01-03 | Vib Vzw | Cd20 binding single domain antibodies |
| BR112019010061A2 (pt) * | 2016-11-16 | 2019-08-13 | Ablynx Nv | polipeptídeos de recrutamento de células t capazes de se ligarem ao cd123 e tcr alfa/beta |
| RU2022101604A (ru) | 2016-12-07 | 2022-03-29 | Аблинкс Нв | Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином |
| IL267897B2 (en) | 2017-01-17 | 2025-02-01 | Ablynx Nv | Improved serum albumin binders |
| JP7219220B2 (ja) | 2017-01-17 | 2023-02-07 | アブリンクス エン．ヴェー． | 改善された血清アルブミン結合剤 |
| KR20210005872A (ko) * | 2018-03-28 | 2021-01-15 | 오리오니스 바이오사이언시즈 인코포레이티드 | 이작용성 단백질 및 이의 작제물 |
| CN109887553B (zh) * | 2019-01-29 | 2021-01-26 | 杭州纽安津生物科技有限公司 | 针对肿瘤靶向药物耐药位点的多肽疫苗及其设计方法 |
| AR120698A1 (es) | 2019-12-09 | 2022-03-09 | Ablynx Nv | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp |
| MX2022007035A (es) * | 2019-12-09 | 2022-06-23 | Ablynx Nv | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp. |
-
2020
- 2020-12-09 MX MX2022007035A patent/MX2022007035A/es unknown
- 2020-12-09 WO PCT/EP2020/085304 patent/WO2021116182A1/en not_active Ceased
- 2020-12-09 TW TW113137609A patent/TW202530257A/zh unknown
- 2020-12-09 MY MYPI2022002971A patent/MY208649A/en unknown
- 2020-12-09 AU AU2020400938A patent/AU2020400938A1/en active Pending
- 2020-12-09 CN CN202080085549.9A patent/CN114980974A/zh active Pending
- 2020-12-09 TW TW109143498A patent/TWI861302B/zh active
- 2020-12-09 EP EP20823785.9A patent/EP4072674A1/en active Pending
- 2020-12-09 US US17/115,906 patent/US20210188965A1/en not_active Abandoned
- 2020-12-09 CA CA3163910A patent/CA3163910A1/en active Pending
- 2020-12-09 KR KR1020227023385A patent/KR20220123237A/ko active Pending
- 2020-12-09 BR BR112022010223A patent/BR112022010223A2/pt unknown
- 2020-12-09 IL IL293548A patent/IL293548A/en unknown
- 2020-12-09 JP JP2022534664A patent/JP7641968B2/ja active Active
-
2021
- 2021-11-19 US US17/530,727 patent/US12384840B2/en active Active
- 2021-11-19 US US17/530,800 patent/US11840566B2/en active Active
- 2021-11-19 US US17/530,850 patent/US12492248B2/en active Active
-
2022
- 2022-06-24 CO CONC2022/0008813A patent/CO2022008813A2/es unknown
-
2025
- 2025-02-20 JP JP2025025563A patent/JP2025081540A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021116182A1 (en) | 2021-06-17 |
| US12492248B2 (en) | 2025-12-09 |
| US20220177565A1 (en) | 2022-06-09 |
| JP2025081540A (ja) | 2025-05-27 |
| JP2023504914A (ja) | 2023-02-07 |
| EP4072674A1 (en) | 2022-10-19 |
| IL293548A (en) | 2022-08-01 |
| TW202136302A (zh) | 2021-10-01 |
| MY208649A (en) | 2025-05-22 |
| US20210188965A1 (en) | 2021-06-24 |
| BR112022010223A2 (pt) | 2022-09-06 |
| CA3163910A1 (en) | 2021-06-17 |
| CO2022008813A2 (es) | 2022-07-19 |
| KR20220123237A (ko) | 2022-09-06 |
| CN114980974A (zh) | 2022-08-30 |
| JP7641968B2 (ja) | 2025-03-07 |
| MX2022007035A (es) | 2022-06-23 |
| US11840566B2 (en) | 2023-12-12 |
| US20220177566A1 (en) | 2022-06-09 |
| AU2020400938A1 (en) | 2022-07-28 |
| TWI861302B (zh) | 2024-11-11 |
| US12384840B2 (en) | 2025-08-12 |
| US20220177564A1 (en) | 2022-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI861302B (zh) | 包含靶向il-13及tslp之免疫球蛋白單可變域的多肽 | |
| US11208476B2 (en) | Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP | |
| JP7817994B2 (ja) | Ｉｌ－１３およびｏｘ４０ｌを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド | |
| CN114981300B (zh) | 包含靶向TNFα和IL-23的免疫球蛋白单个可变结构域的多肽 | |
| JP7842101B2 (ja) | ＩＬ－６およびＴＮＦ－αを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド | |
| US20210188986A1 (en) | Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l | |
| RU2836310C1 (ru) | Полипептиды, содержащие одиночные вариабельные домены иммуноглобулинов, нацеливающиеся на il-13 и tslp | |
| BR122024023752A2 (pt) | Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina que se ligam a il-13 e/ou tslp, método de produção e usos dos mesmos, ácido nucleico, composição e uso da mesma, e hospedeiro ou célula hospedeira |